DiaMedica Therapeutics Inc. - notizie pubblicate 174 - letture 1.755
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results Form 8 K
Diamedica therapeutics provides a business update and announces second quarter 2024 financial results conference call and webcast august 8 at 8:00 am eastern time / 7:00 am central ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
Conference call and webcast august 8 at 8:00 am eastern time / 7:00 am central time acute ischemic stroke (ais) phase 2/3 remedy2 trial interim enrollment (n=144) targeted for q1 2 ...
DIAMEDICA THERAPEUTICS INC.
Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)
Dmtp20240630_10q.htm united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☒quarterly report pursuant to section 13 or 15(d) of the securit ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Minneapolis--(business wire)-- diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company currently focused on developing recombinant klk1 (dm199) for t ...
DIAMEDICA THERAPEUTICS INC.
Supplemental Prospectus - Form 424B3
Dmtp20240716_424b3.htm filed pursuant to rule 424(b)(3) registration statement no.: 333-280744 final prospectus 4,720,000 common shares this prospectus relates to the resale, from ...
DIAMEDICA THERAPEUTICS INC.
Registration Statement Specified Transactions Form S 3
Dmtp20240709_s3.htm as filed with the u.s. securities and exchange commission on july 10, 2024 registration statement no. 333-_________ united states securities and exchange commis ...
DIAMEDICA THERAPEUTICS INC.
Notice of Sales of Unregistered Securities - Form D
Sec form d the securities and exchange commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. the reader shou ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
Minneapolis--(business wire)-- diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic dis ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Announces $11.8 Million Private Placement Form 8 K
Diamedica therapeutics announces $11.8 million private placement minneapolis, minnesota - june 26, 2024 (business wire) - diamedica therapeutics inc. (nasdaq: dmac), a clinical-sta ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Announces $11.8 Million Private Placement
Minneapolis--(business wire)-- diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic dis ...
DIAMEDICA THERAPEUTICS INC.
Material Event Form 8 K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer diamedica therapeuti ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
Preeclampsia program to be initiated with a phase 2 investigator-sponsored trial beginning in q4 2024 key proof-of-concept results expected in the first half of 2025 management wil ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti